Cleft surgery in infants includes special risks due to the kind of the malformation. These risks can be attributed in part to the age and the weight of the patient. Whereas a lot of studies investigated the long-term facial outcome of cleft surgery depending on the age at operation, less is known about the complications arising during a cleft surgery in early infancy.
AbstractBackground
Cleft surgery in infants includes special risks due to the kind of the malformation. These risks can be attributed in part to the age and the weight of the patient. Whereas a lot of studies investigated the long-term facial outcome of cleft surgery depending on the age at operation, less is known about the complications arising during a cleft surgery in early infancy.
Methods
We investigated the incidence and severity of perioperative complications in 174 infants undergoing primary cleft surgery. The severity and the complications were recorded during the intraoperative and the early postoperative period according to the classification by Cohen.
Results
Our study revealed that minor complications occurred in 50 patients. Severe complications were observed during 13 operations. There was no fatal complication in the perioperative period. The risk of complications was found to be directly correlated to the body weight at the time of the surgery. Most of the problems appeared intraoperatively, but they were also followed by complications immediately after the extubation.
Conclusions
In conclusion, cleft surgery in infancy is accompanied by frequent and sometimes severe perioperative complications that may be attributed to this special surgical field.
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.
Head & Face Medicine 2007, 3:9 doi:10.1186/1746-160X-3-9
HP-hMG stimulation reduces OHSS risk in high responder patients
October 25th 2024A recent study found that highly purified human menotropin significantly lowers the risk of ovarian hyperstimulation syndrome compared to recombinant follicle stimulating hormone, highlighting the benefits of protocol individualization based on gonadotropin type.
Read More